SCHEMBL2079581

SCHEMBL2079581

O=[N+]([O-])c1ccc(Cl)cc1/C=N/O

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.53
TSHR P16473 3/20 0.53
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
HPGD P15428 3/20 0.49
PSMD14 O00487 1/20 0.49
BLM P54132 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
BACE1 P56817 1/20 0.49
MAPT P10636 4/20 0.47
LMNA P02545 3/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 4/20 0.43
ALDH1A1 P00352 4/20 0.43
HSP90AA1 P07900 1/20 0.43
POLB P06746 1/20 0.43
VCAM1 P19320 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2079583 1.00 MAPK1 (0.53) MAPK1TSHRMEN1KMT2AHPGD
SCHEMBL31611890 0.87 MAPK1 (0.49) MAPK1TSHRMEN1KMT2AHPGD
SCHEMBL31718055 0.83 MAPK1 (0.53) MAPK1TSHRMEN1KMT2AHPGD
SCHEMBL16801857 0.83 MAPK1 (0.53) MAPK1TSHRMEN1KMT2AHPGD
SCHEMBL16961813 0.81 MAPK1 (0.58) MAPK1TSHRMEN1KMT2AHPGD
SCHEMBL1157544 0.79 MEN1 (0.54) MAPK1TSHRMEN1KMT2AHPGD
SCHEMBL29546973 0.79 MAPK1 (0.60) MAPK1TSHRMEN1KMT2ABACE1
SCHEMBL40312 0.79 MAPK1 (0.60) MAPK1TSHRMEN1KMT2ABACE1
SCHEMBL30435029 0.78 BACE1 (0.57) MAPK1TSHRMEN1KMT2AHPGD
SCHEMBL6377970 0.77 MAPK1 (0.58) MAPK1TSHRMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7906538-B2 Parasiticides; nematocides; crop protection SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2011-03-15 US disclosed
US-20080262048-A1 CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES SCHERING-PLOUGH ANIMAL HEALTH CORPORATION 2008-10-23 US disclosed
EP-1799636-B1 CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES SCHERING PLOUGH LTD (CH) 2008-08-27 EP disclosed
US-7312248-B2 Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2007-12-25 US disclosed
US-7312248-B2 Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2007-12-25 US disclosed
EP-1799636-A2 CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES Schering-Plough Ltd. (CH) 2007-06-27 EP disclosed
WO-2006034333-A2 CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES SCHERING-PLOUGH LTD. (CH) 2006-03-30 WO disclosed
US-20060063841-A1 Parasiticides; nematocides; crop protection SCHERING-PLOUGH LTD. (CH) 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063841-A1 Parasiticides; nematocides; crop protection TRHDE, DDT, EPHX1 MAPK1 3689/4885TSHR 1334/4885MEN1 2617/4885
US-20080262048-A1 CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES TRHDE, EPX, EPHX1 MAPK1 3695/4885TSHR 414/4885MEN1 3201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.